Epidarex Capital
Transatlantic early-stage venture capital firm focused on building life science and health technology companies in emerging hubs. Epidarex provides early-stage investment (often leading Series A rounds), leverages scientific and industry networks, and partners with founders and co-investors to support clinical and commercial development.
Epidarex Capital
Services
Early-stage and Series A equity investment
Provides lead and co-investments in early-stage life science and health technology companies (examples include Series A rounds led by Epidarex).
Access to scientific and industry networks
Connects portfolio companies to scientific, clinical and industry contacts to accelerate development and partnerships.
Strategic guidance and board/advisory support
Provides mentorship, strategic oversight and advisory input to portfolio companies during early clinical and commercial stages.
Co-investor coordination and fundraising support
Works with co-investors to structure and close financing rounds and supports portfolio companies in securing additional funding.
Early-stage and Series A equity investment
Provides lead and co-investments in early-stage life science and health technology companies (examples include Series A rounds led by Epidarex).
Access to scientific and industry networks
Connects portfolio companies to scientific, clinical and industry contacts to accelerate development and partnerships.
Strategic guidance and board/advisory support
Provides mentorship, strategic oversight and advisory input to portfolio companies during early clinical and commercial stages.
Co-investor coordination and fundraising support
Works with co-investors to structure and close financing rounds and supports portfolio companies in securing additional funding.
Portfolio
First patients dosed in Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796.
#Small‑molecule therapeutics / inflammasome inhibition (immunology/obesity)
Treatment of first patient in AERIAL trial of NKG2D CAR‑T therapy LEU011; initiation accelerated by successful first close of Series A1 financing.
#Cell therapy / CAR‑T for solid tumours
Closed a £2 million Series A investment led by Epidarex Capital (April 13, 2015).
#Drug toxicity testing / drug discovery tools
Entered Phase I clinical trial for APL‑2; company raised $33M to fund complement immunotherapy programs; additional investment activity referenced.
#Biotechnology / complement immunotherapy (ophthalmology and autoimmune disease)
Announced additional funding and launch by a drug discovery team focused on new therapeutics for respiratory diseases (February and May 2015 posts).
#Drug discovery / respiratory disease
First patients dosed in Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796.
#Small‑molecule therapeutics / inflammasome inhibition (immunology/obesity)
Treatment of first patient in AERIAL trial of NKG2D CAR‑T therapy LEU011; initiation accelerated by successful first close of Series A1 financing.
#Cell therapy / CAR‑T for solid tumours
Closed a £2 million Series A investment led by Epidarex Capital (April 13, 2015).
#Drug toxicity testing / drug discovery tools
Entered Phase I clinical trial for APL‑2; company raised $33M to fund complement immunotherapy programs; additional investment activity referenced.
#Biotechnology / complement immunotherapy (ophthalmology and autoimmune disease)
Announced additional funding and launch by a drug discovery team focused on new therapeutics for respiratory diseases (February and May 2015 posts).
#Drug discovery / respiratory disease